Immunis Chairman Dr. Hans Keirstead to Speak at the Ending Age-Related Diseases Summit
August 10, 2023IRVINE, Calif.–(BUSINESS WIRE)–#ClinicalTrials—Immunis, Inc., a private biotechnology company pioneering cellular secretome therapies for age and disease-related immune decline, is excited to announce that its Chairman, Dr. Hans Keirstead, will be a panelist at Lifespan.io’s Ending Age-Related Diseases Summit. The summit in New York brings together the world’s foremost experts in the aging field to discuss the cutting-edge developments in longevity research.
The event will serve as a platform for rigorous scientific debate and for collaborative efforts that push the boundaries of human existence. Dr. Keirstead was invited as a C-suite panelist to share his insights on the provocative question: “Is aging truly reversible?” The dialogue between esteemed experts will challenge prevailing perspectives on aging and provide avenues to enhance healthspan. Dr. Keirstead’s exceptional career as a neuroscientist and stem cell researcher, his contributions to the field of regenerative medicine, and his role as Chairman of Immunis make him an exceptional voice for the panel.
Dr. Keirstead is honored to participate in a conference that questions existing viewpoints of aging and maintains optimism about improving quality of life for all.
About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
Contacts